Previous 10 |
home / stock / rvxcf / rvxcf news
Resverlogix is a few days away from releasing topline results from their phase 3 clinical trial, BETonMACE, a trial that aims at showing that Apabetalone (RVX208), a BET bromodomain inhibitor, reduces the risk of heart attacks, stroke and cardiac death in a high-risk population of diabetes pat...
Noteworthy events during the week of August 25 - 31 for healthcare investors. More news on: Daiichi Sankyo Company, Limited, Intellipharmaceutics International Inc., Nektar Therapeutics, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture (the "Debenture") with Sh...
Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to a...
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of a...